About cytodyn inc - CYDY
CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. Its pipeline includes Leronlimab Clinical Development Pipeline and Long-Acting CCR5 Inhibitor Development Pipeline. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
CYDY At a Glance
CytoDyn, Inc.
1111 Main Street
Vancouver, Washington 98660
| Phone | 1-360-980-8524 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | 3.75M | |
| Sector | Health Technology | Employees | 13 | |
| Fiscal Year-end | 05 / 2026 | |||
| View SEC Filings |
CYDY Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 190.00 |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 38.839 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.062 |
CYDY Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | 288,076.923 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CYDY Liquidity
| Current Ratio | 0.254 |
| Quick Ratio | 0.254 |
| Cash Ratio | 0.169 |
CYDY Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | 25.666 |
| Return on Equity | N/A |
| Return on Total Capital | -5.451 |
| Return on Invested Capital | N/A |
CYDY Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -39.797 |
| Total Debt to Total Assets | 151.499 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |